Sep 15, 2025
Apnimed to Participate in Upcoming September Investor Conferences
Sep 03, 2025
Apnimed to Highlight AD109 and the Burden of Obstructive Sleep Apnea (OSA) at World Sleep Congress 2025
Jul 23, 2025
Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea
Jul 01, 2025
Apnimed to Participate in Upcoming July Investor Conferences
Jun 05, 2025
Apnimed Announces Multiple Presentations at the Associated Professional Sleep Societies (SLEEP 2025) Annual Meeting Highlighting the Disease Burden and Current Unmet Medical Needs in Obstructive Sleep Apnea (OSA)
May 19, 2025
Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-daily Oral Pill for Obstructive Sleep Apnea
May 06, 2025
Apnimed Announces Multiple Presentations at the American Thoracic Society (ATS) International Conference 2025 Highlighting Novel Techniques and Unmet Medical Needs in Sleep Medicine
Apr 07, 2025
Apnimed Provides Clinical Updates for Multiple Product Candidates
Mar 26, 2025
Apnimed to Participate in the 24th Annual Needham Virtual Healthcare Conference
Mar 25, 2025
Apnimed to Host Virtual Investor Event Highlighting the Potential for AD109 as a Novel Pharmacotherapy for Obstructive Sleep Apnea on April 11, 2025
Nov 21, 2024
Apnimed to Participate in the 7th Annual Evercore HealthCONx Conference
Oct 23, 2024
Apnimed Strengthens Executive Team and Board of Directors with the Appointment of Two Biopharmaceutical Industry Veterans
Oct 09, 2024
Apnimed Announces Groundbreaking Survey Revealing the Alarming Hidden Impact of Obstructive Sleep Apnea (OSA)
Sep 26, 2024
Apnimed to Participate in the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum
Sep 19, 2024
Apnimed Announces Early Completion of Enrollment in Phase 3 SynAIRgy Study of AD109, the First Potential Oral Treatment Addressing the Neuromuscular Cause of Obstructive Sleep Apnea
Sep 04, 2024
Apnimed to Present New Findings on the Prevalence of Obesity Hypoventilation Syndrome (OHS) at the European Respiratory Society (ERS) Congress 2024